Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Castle Biosciences Inc (CSTL)

Castle Biosciences Inc (CSTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 765,151
  • Shares Outstanding, K 28,007
  • Annual Sales, $ 219,790 K
  • Annual Income, $ -57,470 K
  • EBIT $ 8 M
  • EBITDA $ 15 M
  • 60-Month Beta 0.91
  • Price/Sales 2.49
  • Price/Cash Flow N/A
  • Price/Book 1.75

Options Overview Details

View History
  • Implied Volatility 69.17% ( -1.74%)
  • Historical Volatility 63.60%
  • IV Percentile 31%
  • IV Rank 44.72%
  • IV High 134.09% on 07/15/24
  • IV Low 16.64% on 05/21/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 24
  • Volume Avg (30-Day) 118
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 967
  • Open Int (30-Day) 955

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.11
  • Number of Estimates 1
  • High Estimate 0.11
  • Low Estimate 0.11
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +210.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.08 +13.43%
on 01/17/25
28.90 -5.47%
on 02/03/25
+1.86 (+7.31%)
since 01/14/25
3-Month
23.95 +14.07%
on 01/14/25
32.74 -16.55%
on 01/08/25
-3.51 (-11.39%)
since 11/14/24
52-Week
16.97 +61.04%
on 07/05/24
35.84 -23.77%
on 11/05/24
+3.82 (+16.26%)
since 02/14/24

Most Recent Stories

More News
Axsome Shares Rise 19% in a Month: What's Driving the Rally?

Axsome Therapeutics’ AXSM shares have rallied 19.4% in the past month against the industry’s decrease of 0.2%, driven by investor enthusiasm about the company’s encouraging preliminary sales numbers...

JAZZ : 133.96 (-2.09%)
VYGR : 4.23 (-3.42%)
CSTL : 27.32 (-1.05%)
AXSM : 131.15 (-0.40%)
Is it a Good Idea to Invest in Beam Therapeutics Stock Now?

Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease (SCD), an inherited blood disorder.BEAM’s...

BEAM : 32.40 (+13.25%)
VYGR : 4.23 (-3.42%)
CSTL : 27.32 (-1.05%)
HRMY : 38.98 (-0.24%)
4 Top-Ranked Stocks With Solid Net Profit Margins to Buy Now

The primary purpose of a business is to generate profits that can be reinvested in expansion or utilized for rewarding shareholders. Net profit margin is an effective tool to measure the profits reaped...

OPFI : 13.11 (+0.61%)
CSTL : 27.32 (-1.05%)
GCT : 20.46 (+1.44%)
QFIN : 44.26 (+0.57%)
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?

Massachusett-based Stoke Therapeutics STOK is making rapid progress with the development of zorevunersen (STK-001), its investigational candidate for treating Dravet syndrome, a severe and progressive...

CTMX : 0.7963 (-3.63%)
VYGR : 4.23 (-3.42%)
CSTL : 27.32 (-1.05%)
STOK : 10.68 (+0.47%)
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results

Shares of Mirum Pharmaceuticals MIRM were up 12.1% this week, driven by investor enthusiasm after the company announced encouraging preliminary sales numbers for the fourth quarter and full year 2024,...

CTMX : 0.7963 (-3.63%)
MIRM : 50.04 (-1.30%)
VYGR : 4.23 (-3.42%)
CSTL : 27.32 (-1.05%)
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised)

Acadia Pharmaceuticals ACAD announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval for trofinetide to treat Rett syndrome in...

CTMX : 0.7963 (-3.63%)
VYGR : 4.23 (-3.42%)
CSTL : 27.32 (-1.05%)
ACAD : 20.04 (+1.37%)
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals

Acadia Pharmaceuticals ACAD announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval for trofinetide to treat Rett syndrome in...

CTMX : 0.7963 (-3.63%)
VYGR : 4.23 (-3.42%)
CSTL : 27.32 (-1.05%)
ACAD : 20.04 (+1.37%)
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise

TG Therapeutics TGTX announced preliminary net product revenues for the fourth quarter and full-year 2024 for its marketed drug, Briumvi (ublituximab-xiiy), which exceeded the company’s initial expectations.TGTX...

TGTX : 30.71 (-0.07%)
CTMX : 0.7963 (-3.63%)
VYGR : 4.23 (-3.42%)
CSTL : 27.32 (-1.05%)
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down

SpringWorks Therapeutics SWTX announced preliminary net product revenues for fourth-quarter and full-year 2024 for its sole marketed drug, Ogsiveo (nirogacestat). The drug is approved for treating adult...

CTMX : 0.7963 (-3.63%)
VYGR : 4.23 (-3.42%)
CSTL : 27.32 (-1.05%)
SWTX : 57.43 (-1.98%)
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy

Shares of Blueprint Medicines BPMC rallied 18.2% on Monday driven by investor enthusiasm following the company’s announcement of its 2025 corporate outlook and growth strategy, highlighting plans to...

CTMX : 0.7963 (-3.63%)
CSTL : 27.32 (-1.05%)
BPMC : 93.94 (-1.31%)
HALO : 58.29 (-0.55%)

Business Summary

Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States.

See More

Key Turning Points

3rd Resistance Point 28.58
2nd Resistance Point 28.21
1st Resistance Point 27.77
Last Price 27.32
1st Support Level 26.96
2nd Support Level 26.59
3rd Support Level 26.15

See More

52-Week High 35.84
Fibonacci 61.8% 28.63
Last Price 27.32
Fibonacci 50% 26.40
Fibonacci 38.2% 24.18
52-Week Low 16.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar